10 Best Medical Research Stocks to Buy According to Hedge Funds

3. AbbVie Inc. (NYSE:ABBV)

Number of Hedge Fund Holders: 93

AbbVie Inc. (NYSE:ABBV) is one of the best medical research stocks to buy according to hedge funds. AbbVie Inc. (NYSE:ABBV) received rating updates from Guggenheim and UBS on February 5, with Guggenheim reaffirming a Buy rating on the stock with a $242 price target and UBS revising the price target to $230 from $240 while keeping a Neutral rating on the shares.

Evercore ISI also adjusted the price target on AbbVie Inc. (NYSE:ABBV) on February 4, maintaining an Outperform rating on the stock and lowering the price target to $228 from $232. The firm told investors in a research note that despite Tremfya clearly taking share, the 2026 guidance/consensus still looks beatable, same with 2027. It further stated that it is “worth noting” that the buy-side has been above consensus for a while, and the margin beats look smaller, adding that the real complication is 2028+ growth, especially with more new entrants coming online.

The rating updates came after AbbVie Inc. (NYSE:ABBV) reported its fiscal Q4 and full-year 2025 results on February 4, delivering full-year net revenues of $61.160 billion, up 8.6% on a reported basis and up 8.5% on an operational basis. The company further reported full-year diluted EPS of $2.36 on a GAAP basis, reflecting a decrease of 1.3%, and an adjusted diluted EPS of $10.00, down 1.2%. Management reported that the results included an unfavorable impact of $2.76 per share related to the 2025 acquired IPR&D and milestones expense.

AbbVie Inc. (NYSE:ABBV) is a research-based pharmaceutical company that develops and sells products to treat chronic diseases in oncology, gastroenterology, rheumatology, dermatology, virology, and various other serious health conditions.